CME Group Inc (CME) Expected to Announce Quarterly Sales of $1.02 Billion

Equities analysts expect CME Group Inc (NASDAQ:CME) to post $1.02 billion in sales for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for CME Group’s earnings. The highest sales estimate is $1.03 billion and the lowest is $993.30 million. CME Group reported sales of $900.00 million during the same quarter last year, which would suggest a positive year over year growth rate of 13.3%. The business is expected to report its next quarterly earnings results on Thursday, February 7th.

According to Zacks, analysts expect that CME Group will report full year sales of $4.03 billion for the current fiscal year, with estimates ranging from $3.86 billion to $4.10 billion. For the next fiscal year, analysts anticipate that the company will post sales of $4.53 billion, with estimates ranging from $4.03 billion to $5.05 billion. Zacks Investment Research’s sales averages are an average based on a survey of research firms that that provide coverage for CME Group.

CME Group (NASDAQ:CME) last posted its quarterly earnings results on Thursday, October 25th. The financial services provider reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.03. The business had revenue of $904.20 million during the quarter, compared to the consensus estimate of $910.50 million. CME Group had a net margin of 113.67% and a return on equity of 9.18%.

CME has been the subject of several recent research reports. Zacks Investment Research raised shares of CME Group from a “sell” rating to a “hold” rating in a research note on Wednesday, October 3rd. Bank of America reaffirmed a “buy” rating and set a $200.00 price objective on shares of CME Group in a research note on Monday, November 5th. Berenberg Bank raised shares of CME Group from a “hold” rating to a “buy” rating and set a $220.00 price objective for the company in a research note on Tuesday, November 20th. Jefferies Financial Group upped their price objective on shares of CME Group to $203.00 and gave the company a “buy” rating in a research note on Monday, October 8th. Finally, BidaskClub raised shares of CME Group from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 9th. Six analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $194.13.

CME Group stock opened at $187.11 on Friday. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $63.96 billion, a price-to-earnings ratio of 39.23, a price-to-earnings-growth ratio of 2.19 and a beta of 0.46. CME Group has a twelve month low of $143.68 and a twelve month high of $197.08.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 27th. Investors of record on Monday, December 10th will be given a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a dividend yield of 1.50%. The ex-dividend date of this dividend is Friday, December 7th. CME Group’s dividend payout ratio is currently 58.70%.

In other CME Group news, Director Charles P. Carey sold 2,800 shares of the company’s stock in a transaction dated Friday, November 2nd. The shares were sold at an average price of $183.45, for a total value of $513,660.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Martin J. Gepsman sold 300 shares of the company’s stock in a transaction dated Thursday, September 13th. The stock was sold at an average price of $172.30, for a total transaction of $51,690.00. Following the completion of the sale, the director now owns 42,912 shares in the company, valued at approximately $7,393,737.60. The disclosure for this sale can be found here. Insiders have sold 29,800 shares of company stock worth $5,628,462 in the last quarter. 0.43% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. grew its holdings in CME Group by 1.8% in the third quarter. BlackRock Inc. now owns 22,422,112 shares of the financial services provider’s stock worth $3,816,468,000 after purchasing an additional 403,327 shares during the period. Capital International Investors grew its holdings in CME Group by 18.3% in the third quarter. Capital International Investors now owns 15,425,378 shares of the financial services provider’s stock worth $2,625,554,000 after purchasing an additional 2,383,280 shares during the period. Capital Research Global Investors grew its holdings in CME Group by 107.8% in the third quarter. Capital Research Global Investors now owns 10,906,683 shares of the financial services provider’s stock worth $1,856,427,000 after purchasing an additional 5,658,108 shares during the period. Edgewood Management LLC grew its holdings in CME Group by 9.5% in the third quarter. Edgewood Management LLC now owns 8,582,518 shares of the financial services provider’s stock worth $1,460,830,000 after purchasing an additional 742,067 shares during the period. Finally, Janus Henderson Group PLC grew its holdings in CME Group by 3.3% in the third quarter. Janus Henderson Group PLC now owns 6,331,522 shares of the financial services provider’s stock worth $1,077,689,000 after purchasing an additional 202,365 shares during the period. Institutional investors and hedge funds own 85.89% of the company’s stock.

CME Group Company Profile

CME Group Inc, through its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers a range of products across various asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural products, and metals.

Recommended Story: Should You Consider an Index Fund?

Get a free copy of the Zacks research report on CME Group (CME)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CME Group (NASDAQ:CME)

Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply